Over the past decade, the discussion around vaping has evolved from mostly a theory about reducing harm to one backed by a wealth of real-world data and research. Studies from toxicology, clinical trials, and population surveys have all pointed out that vaping carries much lower risks than smoking traditional cigarettes.
Currently, the debates are largely centred around two main areas. One looking into potential long-term health risks, like cancer or respiratory problems, that might arise from vaping over time. The other focused on how effective vaping is for people trying to quit smoking and/or reducing their exposure to harmful chemicals. Overall, these studies indicate that while not entirely risk-free, vaping plays an important role in smoking cessation and lessening smoking-related harm for people unable to give up nicotine.
Does vaping cause cancer?
Studies looking at biomarkers of inflammation among vapers compared to non-smokers suggest that these levels fall short of what’s seen in cigarette smokers.
Meanwhile, the possibility of long-term cancer risks linked to vaping has naturally been widely debated. A recent review conducted by Australian researchers drew attention after concluding that laboratory evidence surrounding vaping and cancer risk is strong enough to justify stronger concern. The researchers argued that studies examining the biological effects of e-cigarette exposure increasingly point toward carcinogenic potential. However, there was no clear indicators of causation.
In fact, tobacco harm reduction experts also stress that to date, there is still no evidence indicating that vaping causes cancer in humans. Smoking-related cancer research spans decades, while widespread e-cigarette use is comparatively recent. Oncologists and public health specialists generally describe the current evidence as incomplete, but to date, research has consistently shown that vaping presents a lower cancer risk than smoking. In fact, studies looking at biomarkers of inflammation among vapers compared to non-smokers suggest that these levels fall short of what’s seen in cigarette smokers.
Unprecedented success for smoking cessation
Alongside all this toxicology research is a growing amount of clinical evidence looking at whether vaping helps smokers kick the habit or at least cut back on their cigarette use. A
comprehensive review led by Mimi M. Kim and her team at Thera-Business analysed 214 different studies, including 22 randomised controlled trials and found that smokers who used nicotine vapes along with behavioural support had significantly better odds of quitting compared to those who only got behavioural help. In many cases, quit rates were about two or three times higher when vaping was part of the strategy—this was consistent across follow-ups ranging from three months out to six months or longer.
The review also showed that even if smokers didn’t fully quit, those who vaped reduced their daily cigarette consumption by 4 or 5 cigarettes per day, compared with control groups, and maintained those reductions over time. This points to the idea that even if people only use these products part-time, they can still make a real difference in reducing their exposure to harmful chemicals from smoking.
Looking at vaping compared to good old nicotine replacement options like gum or patches, the results aren’t exactly clear-cut. Some studies didn’t present vaping as the best option across the board, while others pointed out better quit rates or more significant reductions in cravings for those who opted for vapes. Researchers pointed out that these inconsistencies often stemmed from differences in study designs—things like adherence levels and contamination, where participants assigned to non-vaping groups ended up using e-cigarettes anyway. Despite this messiness, the general takeaway was clear: vaping holds its own against conventional nicotine replacement therapies and does significantly better in most cases.
Real-world data support the findings
More importantly, clinical findings align increasingly with what we’re seeing at the population level! Countries like Sweden, the UK, Japan, and New Zealand have shown huge drops in smoking rates, coinciding directly with smoke-free alternative uptake, such as vapes, heated tobacco and nicotine pouches. For instance, Sweden now boasts an unprecedented 3.7% smoking prevalence, attributed largely to the use of snus and nicotine pouches, while Japan has witnessed steep declines following heated options rolling onto the market.
A separate randomised
clinical trial published by the Penn State College of Medicine added further insights into modern pod-based nicotine salt systems—devices known for their efficient nicotine delivery. This study saw some significant differences when it came to quitting outcomes: 36.5 per cent of participants using nicotine-containing pods stopped smoking within six weeks versus only 11.5 per cent among those using placebo devices with no nicotine at all—and this trend held steady through follow-ups.
The research team also measured NNAL levels, a biomarker strongly associated with tobacco-related carcinogens, and found that participants who switched completely from cigarettes to vaping showed marked reductions compared with control groups. This reinforces the idea that combustion is really what drives smoking-related harm.
There has also been vast research on how vaping might affect cardiovascular health, especially via blood pressure. A handful of observational studies have found some connections between nicotine use and higher blood pressure levels. But experts in the field suggest we shouldn’t rush to conclusions based solely on these observations, while others have consistently suggested that nicotine does not raise blood pressure any more than any other mild stimulant, such as caffeine, would.
In contrast, there has been vast research into the positive effects of nicotine on cognitive health. Experiments in controlled settings indicate that low doses of nicotine actually sharpen attention, boost working memory, and even elevate mood—especially in individuals dealing with mild cognitive impairment. These findings fit well within broader discussions of neurobiology, especially when considering how dopamine pathways contribute to motivation and attention.
The bottom line
Ultimately, when all the research is considered, from lab studies to clinical trials and even population stats, the fact that vaping is significantly safer than cigarettes is an effective smoking cessation tool is undeniable. So, what is the main takeaway? Smokers who switch completely from regular cigarettes to vaping are exposed to considerably fewer harmful toxins and have a better shot at quitting for good! The real challenge now is figuring out what those long-term risks might be while also maximising how effective vaping can be in helping people kick the habit.
